Table 4.
Risk factors for severe RSV infection and eligibility for PZ prophylaxis (n = 62)
| Risk factor |
<2 years of age at the beginning of RSV season n (%) |
2013 K‐NHIS (South Korea) n (%) |
2015 EMA (EU) n (%) |
2014 AAP (USA) n (%) |
|---|---|---|---|---|
| PM (weeks’ GA) | 5 (8.1) | 3 (12.5) | 5 (19.2) | 2 (6.7) |
| <29 | 2 (3.2) | 2 (8.3) | 2 (7.7) | 2 (6.7) |
| 29–31 | 1 (1.6) | 1 (4.2) | 1 (3.8) | 0 (0.0) |
| 32–35 | 2 (3.2) | 0 (0.0) | 2 (7.7) | 0 (0.0) |
| CLD | 7 (11.3) | 7 (29.2) | 7 (26.9) | 7 (23.3) |
| PM related | 6 (9.7) | 6 (25.0) | 6 (23.1) | 6 (20.0) |
| Non‐PM related | 1 (1.6) | 1 (4.2) | 1 (3.8) | 1 (3.3) |
| HS‐CHD† | 14 (22.6) | 14 (58.3) | 14 (53.8) | 14 (46.7) |
| Other | 9 (14.5) | 0 (0.0) | 0 (0.0) | 7 (23.3) |
| NMD‡ | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (3.2) |
| CAA | 6 (9.7) | 0 (0.0) | 0 (0.0) | 6 (20.0) |
| Profoundly immunocompromised | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Down syndrome§ | 2 (3.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Underlying disease without risk factor¶ | 4 (6.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No underlying disease (no risk factor) | 23 (37.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total | 62 (100.0) | 24 (38.7) | 26 (41.9) | 30 (48.4) |
†One patient had two risk factors: pulmonary hypertension and congenital mitral regurgitation with laryngomalacia. ‡One patient had two risk factors: mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (MELAS) with hypertrophic cardiomyopathy. §Without congenital heart disease. ¶Prematurity at 36 weeks and 0 days of gestation, n = 1; simple ventricular septal defect, n = 1; nephrotic syndrome, n = 1; and renal tubular acidosis type 3, n = 1. AAP, American Academy of Pediatrics; CAA, congenital abnormalities of the airway; CLD, chronic lung disease; EMA, European Medicines Agency; GA, gestational age; HS‐CHD, hemodynamically significant congenital heart disease; K‐NHIS, National Healthcare Insurance Service in South Korea; NMD, neuromuscular disorders; PM, prematurity; PZ, palivizumab; RSV, respiratory syncytial virus.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.